Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 1, 2024

IPF and PDE4B Inhibitors

Author(s)Steven D. Nathan, MD

Dr Nathan highlights the role of PDE4B inhibitors in IPF management.

Episodes in this series

Justin Oldham, MD, MS, an expert on IPF

EP. 1 Emerging Agents in IPF Treatment

Justin Oldham, MD, MS, an expert on IPF

EP. 2 IPF and PDE4B Inhibitors

Justin Oldham, MD, MS, an expert on IPF

EP. 3 Importance of Patient-Reported Outcomes

Justin Oldham, MD, MS, an expert on IPF

EP. 4 Future Possibilities in IPF Treatment

Justin Oldham, MD, MS, an expert on IPF

EP. 5 Advice for Clinicians Treating IPF

Justin Oldham, MD, MS, an expert on IPF

EP. 6 Current Standard of Care in IPF

Justin Oldham, MD, MS, an expert on IPF

EP. 7 Therapeutic Response and Disease Progression

Justin Oldham, MD, MS, an expert on IPF

EP. 8 Key Considerations for Selecting IPF Treatment

Justin Oldham, MD, MS, an expert on IPF

EP. 9 Economic Impact of IPF

Justin Oldham, MD, MS, an expert on IPF

EP. 10 Unmet Needs in IPF Landscape

Justin Oldham, MD, MS, an expert on IPF

EP. 11 Overview of Idiopathic Pulmonary Fibrosis (IPF)

Justin Oldham, MD, MS, an expert on IPF

EP. 12 Impact of IPF on Quality of Life and Financial Considerations

Justin Oldham, MD, MS, an expert on IPF

EP. 13 Diagnosing IPF: Key Tests, Time to Diagnosis, and Importance of Early Detection

Justin Oldham, MD, MS, an expert on IPF

EP. 14 Clinical Presentation and Risk Factors

Justin Oldham, MD, MS, an expert on IPF

EP. 15 Impact of Comorbidities on IPF Management

Justin Oldham, MD, MS, an expert on IPF

EP. 16 Overcoming Treatment Barriers: Strategies for Success

Justin Oldham, MD, MS, an expert on IPF

EP. 17 Impact of Treatment Delays on Patient Outcomes

Video content above is prompted by the following:

What is the rationale for studying the phosphodiesterase 4 (PDE4) inhibitor pathway in idiopathic pulmonary fibrosis (IPF)?
How do PDE4 inhibitors differ from PDE4B inhibitors?
Why is this pathway of interest to pulmonologists and patients living with IPF?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Doctor phone call. | Image credit: @AndreyPopov_AdobeStock.jpeg

Voice Biomarkers Show Promise for Asthma, COPD Exacerbation Detection

BySabrina McCrear

July 16th 2026

Blue FDA approved stamp | Image credit: Surendra-stock.adobe.com

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

ByLaura Joszt, MA

July 16th 2026

Experts featured in this series.

Why Clinicians May Consider Obinutuzamab Over Rituximab in Follicular Lymphoma

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

July 16th 2026

Experts featured in this series.

Managing the Tafasitamab Triplet: Safety Profile, Adverse Events, and Clinical Implications from inMIND

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

July 16th 2026

Man using breathing assistant device. | Image credit: @DebraAnderson_AdobeStock.jpeg

Respiratory Rehabilitation Benefits Patients With COPD and Suspected PH

BySabrina McCrear

July 15th 2026

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

Home-Based Heart Failure Care Shows Comparable Safety to Continued Inpatient Care

Cardiology Prices Vary Widely by Insurer and State

Voice Biomarkers Show Promise for Asthma, COPD Exacerbation Detection

Rethinking Cardiometabolic Risk: Deepak Bhatt, MD, MPH, MBA